Craving for a Robust Methodology: A Systematic Review of Machine Learning Algorithms on Substance-Use Disorders Treatment Outcomes

Bernardo Paim de Mattos, Christian Mattjie, Rafaela Ravazio, Rodrigo C. Barros, Rodrigo Grassi‐OliveiraInternational Journal of Mental Health and Addiction 2024 · DOI

Abstract

Substance use disorders (SUDs) pose significant mental health challenges due to their chronic nature, health implications, impact on quality of life, and variability of treatment response. This systematic review critically examines the application of machine learning (ML) algorithms in predicting and analyzing treatment outcomes in SUDs. Conducting a thorough search across PubMed, Embase, Scopus, and Web of Science, we identified 28 studies that met our inclusion criteria from an initial pool of 362 articles. The MI-CLAIM and CHARMS instruments were utilized for methodological quality and bias assessment. Reviewed studies encompass an array of SUDs, mainly opioids, cocaine, and alcohol use, predicting outcomes such as treatment adherence, relapse, and severity assessment. Our analysis reveals a significant potential of ML models in enhancing predictive accuracy and clinical decision-making in SUD treatment. However, we also identify critical gaps in methodological consistency, transparency, and external validation among the studies reviewed. Our review underscores the necessity for standardized protocols and best practices in applying ML within SUD while providing recommendations and guidelines for future research.

Introduction

Substance use disorders (SUDs) are notoriously difficult to treat due to their chronic nature and the high variability in how individuals respond to interventions. Clinicians struggle to predict which patients are at high risk for relapse or treatment dropout. While Machine Learning (ML) offers a powerful toolkit for identifying patterns in complex data—ranging from clinical histories to fMRI scans—the current body of research is fragmented. This review highlights a "craving for robustness," noting that while many models claim high accuracy, they often suffer from methodological flaws that prevent real-world clinical utility.

Methods

This systematic review applies a rigorous "meta-lens" to existing research. Following PRISMA guidelines, the authors screened 362 articles down to a final selection of 28 studies.

PRISMA flow diagram illustrating the systematic search and selection process for the 28 included studies.

To evaluate study quality, two specialized frameworks were employed:

  • MI-CLAIM: A checklist for clinical AI modeling to ensure transparency and rigor.
  • CHARMS: A tool for assessing bias and clinical applicability of prediction models.

Studies were categorized by the substances involved (primarily opioids, alcohol, and cocaine) and the clinical outcomes predicted (adherence, relapse, severity, and diagnosis).

Data Sources and Methodological Challenges

The reviewed studies utilized a mix of public and private datasets, including the Treatment Episode Data Set - Discharges (TEDS-D), the COMBINE Trial for alcohol use, and the GAIN dataset. Emerging research also incorporates multimodal data such as fMRI, EEG, and "digital phenotyping" from wearables.

However, several critical methodological issues were identified:

  • Data Leakage: Some studies used "Length of Stay" (LOS) as a feature to predict treatment completion. This is logically flawed; LOS is only known after treatment ends, making the model useless for early clinical intervention.
  • The Accuracy Trap: In datasets where 90% of patients succeed, a model can achieve 90% accuracy by simply guessing "success" every time, failing to identify the high-risk 10% who actually need help.
  • Contextual Confounding: One study achieved 96% accuracy in identifying Opioid Use Disorder (OUD), but the OUD group was recruited from psychiatric facilities while the control group was from the community. The model likely learned to distinguish "institutionalized" vs. "non-institutionalized" individuals rather than the neurobiology of addiction.

Key Results and Algorithm Performance

The most common targets for ML were Treatment Adherence (32%) and Relapse (18%). Performance varied significantly:

  • Adherence: Top models reached AUCs of 0.80 to 0.89 using ensemble methods like XGBoost or Random Forest.
  • Relapse: These models often struggled, with some showing performance barely better than random chance (AUC ~0.51).
  • Algorithms: While Deep Learning (CNNs) is growing in neuroimaging applications, "shallow" ensemble methods like Random Forest and XGBoost remain the gold standard for tabular clinical data due to their interpretability and performance.

Conclusion and Future Directions

To move from experimental models to clinical tools, the field must address several gaps:

  1. External Validation: Models must be tested on independent datasets from different regions to ensure generalizability.
  2. Transparency: Code and anonymized data sharing are essential for replication.
  3. Nuanced Outcomes: Research should shift from binary "completion" metrics to broader recovery markers like quality of life and social reintegration.
  4. Standardized Reporting: Adopting protocols like MI-CLAIM and CHARMS is vital to ensure ML applications in psychiatry are as robust as the medical interventions they support.

Summary updated

Abstract

Abstract Substance use disorders (SUDs) pose significant mental health challenges due to their chronic nature, health implications, impact on quality of life, and variability of treatment response. This systematic review critically examines the application of machine learning (ML) algorithms in predicting and analyzing treatment outcomes in SUDs. Conducting a thorough search across PubMed, Embase, Scopus, and Web of Science, we identified 28 studies that met our inclusion criteria from an initial pool of 362 articles. The MI-CLAIM and CHARMS instruments were utilized for methodological quality and bias assessment. Reviewed studies encompass an array of SUDs, mainly opioids, cocaine, and alcohol use, predicting outcomes such as treatment adherence, relapse, and severity assessment. Our analysis reveals a significant potential of ML models in enhancing predictive accuracy and clinical decision-making in SUD treatment. However, we also identify critical gaps in methodological consistency, transparency, and external validation among the studies reviewed. Our review underscores the necessity for standardized protocols and best practices in applying ML within SUD while providing recommendations and guidelines for future research.
BibTeX
@article{mattos2024craving,
  author = {Bernardo Paim de Mattos and Christian Mattjie and Rafaela Ravazio and Rodrigo C. Barros and Rodrigo Grassi‐Oliveira},
  title = {{Craving for a Robust Methodology: A Systematic Review of Machine Learning Algorithms on Substance-Use Disorders Treatment Outcomes}},
  journal = {International Journal of Mental Health and Addiction},
  year = {2024},
  doi = {10.1007/s11469-024-01403-z},
}
Figure